Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
Open Access
- 22 April 2010
- journal article
- Published by Springer Science and Business Media LLC in BMC Endocrine Disorders
- Vol. 10 (1), 7
- https://doi.org/10.1186/1472-6823-10-7
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year studyInternational Journal of Clinical Practice, 2010
- GLP-1: Broadening the incretin concept to involve gut motilityRegulatory Peptides, 2009
- Benign Skin Lesions: Lipomas, Epidermal Inclusion Cysts, Muscle and Nerve BiopsiesSurgical Clinics of North America, 2009
- Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and KoreaDiabetes Research and Clinical Practice, 2009
- Incidence, aetiology and epidemiology of uterine fibroidsBest Practice & Research Clinical Obstetrics & Gynaecology, 2008
- Efficacy and Safety of Incretin Therapy in Type 2 DiabetesJAMA, 2007
- Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes, Obesity and Metabolism, 2007
- The Role of Obesity and Related Metabolic Disturbances in Cancers of the Colon, Prostate, and PancreasGastroenterology, 2007
- Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trialDiabetes, Obesity and Metabolism, 2007
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia, 2006